A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
Recruiting · NCT06465550 · Registry updated 2024-06-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major | β-thalassemia | Recruiting | Phase 1 | 2024-06-24 | NCT06465550 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai BDgene Co., Ltd. | 5 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shanghai Ruijin Hospital, Shanghai Jiaotong University | Shanghai | China | 1 |
| Sun Yat-sen Memorial Hospital | Guangzhou | China | 1 |
| The First Affiliated Hospital of Guangxi Medical University | Nanning | China | 66 |